Goodwill and Other Intangible Assets

6 Months Ended

Jun. 30, 2015

Goodwill and Other Intangible Assets

5.Goodwill and Other Intangible Assets

Our goodwill as of June 30, 2015 and December 31, 2014, by reporting segment, consists of the following:


	Medical		Clinical
	Equipment		Engineering		Surgical
(in thousands)	Solutions		Solutions		Services		Total
Balance at December 31, 2014	$	227,486	$	55,655	$	52,436	$	335,577
Acquisition		—		—		1,018		1,018
Balance at June 30, 2015	$	227,486	$	55,655	$	53,454	$	336,595

Our other intangible assets as of June 30, 2015 and December 31, 2014 consist of the following:


	June 30, 2015								December 31, 2014
			Accumulated								Accumulated
(in thousands)	Cost		Amortization		Impairment		Net		Cost		Amortization		Impairment		Net
Finite-life intangibles
Customer relationship	$	117,039	$	(85,324)	$	—	$	31,715	$	115,731	$	(80,704)	$	—	$	35,027
Supply agreement		26,000		(20,917)		—		5,083		26,000		(19,464)		—		6,536
Technology databases		7,217		(7,217)		—		—		7,217		(7,217)		—		—
Non-compete agreements		948		(614)		—		334		780		(538)		—		242
Favorable lease agreements		134		(134)		—		—		134		(134)		—		—
Total finite-life intangibles		151,338		(114,206)		—		37,132		149,862		(108,057)		—		41,805
Indefinite-life intangibles
Trade names		166,000		—		(34,900)		131,100		166,000		—		(34,900)		131,100
Total intangible assets	$	317,338	$	(114,206)	$	(34,900)	$	168,232	$	315,862	$	(108,057)	$	(34,900)	$	172,905

Total amortization expense related to intangible assets were $3.0 and $3.3 million for the three months ended June 30, 2015 and 2014, respectively and $6.1 and $6.6 million for the six months ended June 30, 2015 and 2014, respectively.

The estimated future amortization expense for identifiable intangible assets during the remainder of 2015 and the next five years is as follows:


(in thousands)
Remainder of 2015	$	5,878
2016		10,971
2017		7,679
2018		6,095
2019		3,529
2020		1,537

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details